Alzheon presents new data for ALZ-801 on novel MOA and long-term clinical efficacy at the AAIC
Presentations highlight recent discovery of inhibition of formation of toxic beta amyloid oligomers and new insights for Precision Medicine approach for ALZ-801 targeting APOE4 carriers.
Alzheon has announced data from the company’s three presentations at the Alzheimer’s Association International Conference (AAIC) in London, 16-20 July 2017.
These presentations at AAIC represent the convergence of research efforts by Alzheon for ALZ-801, an anti-amyloid drug candidate that is an optimized prodrug of tramiprosate, with R&D findings that range from the discovery of a novel molecular mechanism of action, to long-term clinical efficacy data in patients with Alzheimer’s disease (AD). Together, these analyses confirm a Precision Medicine approach with ALZ-801 by showing the clinical efficacy of tramiprosate in a genetically-defined subpopulation of patients with apolipoprotein E4 (APOE4) genotype, and aligning the role of APOE4 and beta amyloid pathology in AD, through the following key observations:
“All of our research and insights have brought us to the point where we can confirm how ALZ-801 blocks Alzheimer’s amyloid pathology, and confidently pursue our goal of directing an oral medicine for the Alzheimer’s patients who will most benefit from the treatment,” said Martin Tolar, Founder, President and CEO of Alzheon. “Our efforts have spanned the continuum – from understanding the molecular mechanism of action of inhibiting oligomers, to revealing clinical efficacy in the genetically-defined population of APOE4/4 homozygotes, and showing strong effects in those patients with Mild disease – enabling us to understand how our treatment works. Together, these observations position us to developing ALZ-801 along a highly focused and targeted clinical path, as we move toward a pivotal study as quickly as possible to address the urgent needs of patients.”
Alzheon will make two presentations at AAIC related to the novel beta amyloid anti-oligomer mechanism of action of ALZ-801. The presentations highlight Alzheon’s discovery of the novel molecular mechanism of action of tramiprosate, the active agent in the optimized prodrug ALZ-801, blocking formation of toxic amyloid oligomers, which play a key role early in the Alzheimer’s disease process. At the AAIC, Alzheon will expand on its recently-published mechanism of action of tramiprosate, demonstrating that tramiprosate acts through a novel enveloping mechanism to inhibit beta amyloid monomer aggregation and formation of toxic amyloid oligomers at clinically relevant doses. Further results demonstrated that the concentrations of tramiprosate in the brain were sufficient to elicit the full inhibition of oligomer formation, and confirmed the dose selection of ALZ-801 for the confirmatory Phase III program planned in AD patients.
Alzheon will also make a presentation on new clinical analyses supporting the company’s Precision Medicine clinical program for ALZ-801, further expanding on Alzheon’s body of research from previous tramiprosate Phase III studies showing an APOE4 gene dose effect, with the largest clinical benefit observed in APOE4/4 homozygotes. Alzheon will present details from the recently-published analyses of Phase III data that showed the largest efficacy signals of tramiprosate in APOE4/4 homozygous patients with Mild Alzheimer’s disease. In addition, at the AAIC, Alzheon will present analyses of efficacy and safety in APOE4/4 homozygotes with AD from the Phase 3 studies who continued into an Extension Study for an additional 52 weeks, when all subjects received high dose of tramiprosate. Results from the Extension Study showed that APOE4/4 AD subjects who received the high dose of tramiprosate over 130 weeks, showed persistent efficacy compared to subjects who had a delayed start on active drug (i.e., initial placebo-treated subjects), suggesting a disease-modification effect.
Related News
-
News CPHI Frankfurt: Interview with Marcelo Cruz, Vice President, Business Development & Marketing at Tjoapack
In this series of interviews, we caught up with some of the exhibitors at CPHI Frankfurt to discover what innovations are being brought to the pharmaceutical industry this year. Here we chat with Marcelo Cruz of Tjoapack to discuss how global events ar... -
News CPHI Frankfurt 2022: Innovator Interviews – Bioiberica
In this series of interviews, we speak to the companies on the CPHI Frankfurt show floor who are driving innovation in pharma for a better healthcare future. We caught up with Mónica Gómez Navarro (Marketing Manager Branded Ingredients), ... -
News CPHI Frankfurt 2022: Innovator Interview – Procaps Group
In this series of interviews, we speak to the companies on the CPHI Frankfurt show floor who are driving innovation in pharma for a better healthcare future. We interviewed Rosella Del Vecchio Herrera, Marketing Director at Procaps Group, to discover h... -
News From the floor - CPHI Frankfurt 2022
The live blog from the people on the ground at CPHI Frankfurt - covering all stand-out news, memorable moments, and keynote updates from the 2022 event. -
News How to Commercialise an Advanced Therapy: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Andrea Zobel, Senior Director, Personalized Supply Chain at World Courier (Berlin Germany), Melissa Lattanzi, VP Emerging Therapies at AmerisourceBergen (King of Prussia, USA), and Hans-Peter Scherzer, Customer Suc... -
News CDMO - Health is a Joint Project: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Emanuele Agnese, Business Development Manager and Pietro Allegrini, R&D Director at Indena, present the ways in which a reliable manufacturing partner in the pursuit of better health outcomes for patients and pharm... -
News Streamlined Development for Efficient Production of Bispecific Molecules: Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Séverine Fagète, VP, Cell Line Development Services at Selexis (Geneva, Switzerland), and Brandon Brino (Durham, USA), Process Development Scientist and Group Leader at KBI Biopharma, present an overv... -
News MDR – How to collect post-market clinical follow-up data (PMCF): Connect to Frankfurt on-demand
In this Connect to Frankfurt session, Philipp Annecke, Junior Key Account Manager and Heinrich Martens, VP Regulatory Affairs of Fresenius Kabi (Bad Homburg, Germany) present guidances from the Medical Devices Regulation on clinical data evaluatio...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance